PharmaCyte Biotech, Inc. (PMCB)

NASDAQ: PMCB · Real-Time Price · USD

0.8500

+0.0100 (1.19%)

At close: Aug 13, 2025, 4:00 PM

0.8400

-0.0100 (-1.18%)

Pre-market: Aug 14, 2025, 8:09 AM EDT

PharmaCyte Biotech Income Statement

Financials in millions USD. Fiscal year is May - April.

Millions USD. Fiscal year is May - Apr.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2016 - 2020
Period Ending	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022	Apr '21 Apr 30, 2021	2016 - 2020
Selling, General & Admin	3.94	6.11	5.99	3.7	2.71	Upgrade
Research & Development	0.44	0.41	0.47	0.69	0.92	Upgrade
Operating Expenses	4.38	6.52	6.46	4.39	3.62	Upgrade
Operating Income	-4.38	-6.52	-6.46	-4.39	-3.62	Upgrade
Interest Expense	-	-	-	-0	-0	Upgrade
Interest & Investment Income	1.42	3.4	1.94	0.16	-	Upgrade
Other Non Operating Income (Expenses)	9.11	5.45	0.2	-0	-0	Upgrade
EBT Excluding Unusual Items	6.15	2.33	-4.32	-4.24	-3.63	Upgrade
Gain (Loss) on Sale of Investments	26.53	-	-	-	-	Upgrade
Asset Writedown	-	-2	-	-	-	Upgrade
Legal Settlements	-2.02	-	-	-	-	Upgrade
Other Unusual Items	-	-	-	-	0.08	Upgrade
Pretax Income	30.66	0.33	-4.32	-4.24	-3.55	Upgrade
Net Income	30.66	0.33	-4.32	-4.24	-3.55	Upgrade
Preferred Dividends & Other Adjustments	7.29	17.57	-	-	-	Upgrade
Net Income to Common	23.36	-17.24	-4.32	-4.24	-3.55	Upgrade
Net Income Growth	9084.98%	-	-	-	-	Upgrade
Shares Outstanding (Basic)	7	10	19	16	1	Upgrade
Shares Outstanding (Diluted)	7	10	19	16	1	Upgrade
Shares Change (YoY)	-23.50%	-50.84%	25.56%	971.73%	60.24%	Upgrade
EPS (Basic)	3.19	-1.80	-0.22	-0.27	-2.45	Upgrade
EPS (Diluted)	3.19	-1.80	-0.22	-0.27	-2.45	Upgrade
EBIT	-4.38	-6.52	-6.46	-4.39	-3.62	Upgrade

Updated Aug 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q